Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Back to 584 patent claim 29

Back to 584 patent claim 29

posted on Jul 17, 2007 09:47AM
I was looking over the request for review and in particular the pages referenced by the USPTO in the 6/26 rejection of claims 29.  To me it seems like the defendant is pointing to exceptions to the norm (branch instructions) as the basis for the initial review.  What the 584 does routinely sort a happens if you look only at branch instruction methodology.  Has anyone with a greater understanding of the patents looked at the request and specifically those pages/paragraphs referenced in the 6/26 rejections?  I would appreciate any comments with respect to whether my interpetation is correct.  TIA Opty
Share
New Message
Please login to post a reply